• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surviving the storm: Dealing with COVID-19.

作者信息

Vandenbark Arthur A, Meza-Romero Roberto, Offner Halina

机构信息

Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

出版信息

Cell Immunol. 2020 Aug;354:104153. doi: 10.1016/j.cellimm.2020.104153. Epub 2020 Jun 13.

DOI:10.1016/j.cellimm.2020.104153
PMID:32563849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293470/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/267b/7293470/84e2fb5a1a7f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/267b/7293470/84e2fb5a1a7f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/267b/7293470/84e2fb5a1a7f/gr1_lrg.jpg

相似文献

1
Surviving the storm: Dealing with COVID-19.挺过风暴：应对新冠疫情
Cell Immunol. 2020 Aug;354:104153. doi: 10.1016/j.cellimm.2020.104153. Epub 2020 Jun 13.
2
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
3
Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.一名患有新型冠状病毒2型相关多系统炎症综合征儿童的白细胞红细胞增多症和浆细胞样淋巴细胞
Blood. 2020 Aug 13;136(7):914. doi: 10.1182/blood.2020007132.
4
Cytokine storm intervention in the early stages of COVID-19 pneumonia.COVID-19 肺炎早期的细胞因子风暴干预。
Cytokine Growth Factor Rev. 2020 Jun;53:38-42. doi: 10.1016/j.cytogfr.2020.04.002. Epub 2020 Apr 25.
5
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.熊去氧胆酸作为一种缓解和/或预防新冠病毒相关细胞因子风暴的候选治疗药物。
Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.
6
SARS-CoV-2: An immunogenetics call to arms.SARS-CoV-2：免疫遗传学的宣战。
Int J Immunogenet. 2020 Aug;47(4):319-323. doi: 10.1111/iji.12504. Epub 2020 Jul 12.
7
After 62 years of regulating immunity, dexamethasone meets COVID-19.地塞米松调控免疫 62 年后迎击 COVID-19。
Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.
8
Should we unstress SARS-CoV-2 infected cells?我们是否应该减轻感染了新冠病毒的细胞的应激反应？
Cytokine Growth Factor Rev. 2020 Aug;54:3-5. doi: 10.1016/j.cytogfr.2020.06.011. Epub 2020 Jun 11.
9
Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?新型冠状病毒2感染的急性炎症与发病机制：大麻二酚能否作为一种潜在的抗炎治疗方法？
Cytokine Growth Factor Rev. 2020 Jun;53:63-65. doi: 10.1016/j.cytogfr.2020.05.008. Epub 2020 May 20.
10
Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.新型冠状病毒肺炎患者细胞因子释放综合征：感染与自身免疫之间脆弱平衡的新挑战
Int J Mol Sci. 2020 May 8;21(9):3330. doi: 10.3390/ijms21093330.

引用本文的文献

1
Proteomics research of SARS-CoV-2 and COVID-19 disease.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与冠状病毒病（COVID-19）的蛋白质组学研究
Med Rev (2021). 2022 Sep 14;2(4):427-445. doi: 10.1515/mr-2022-0016. eCollection 2022 Aug.
2
Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19.蛋白质组学研究揭示了新冠肺炎患者中性粒细胞脱颗粒和mRNA翻译途径的主要改变。
iScience. 2021 Mar 19;24(3):102135. doi: 10.1016/j.isci.2021.102135. Epub 2021 Feb 4.
3
SARS-CoV-2 Infection: Symptoms of the Nervous System and Implications for Therapy in Neurological Disorders.

本文引用的文献

1
Severe COVID-19: A Review of Recent Progress With a Look Toward the Future.严重的 COVID-19：近期进展回顾及未来展望。
Front Public Health. 2020 May 13;8:189. doi: 10.3389/fpubh.2020.00189. eCollection 2020.
2
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
3
A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.
严重急性呼吸综合征冠状病毒2感染：神经系统症状及其对神经系统疾病治疗的影响
Neurol Ther. 2021 Jun;10(1):31-42. doi: 10.1007/s40120-020-00225-0. Epub 2020 Nov 23.
一种用于多发性硬化症、缺血性损伤、甲基苯丙胺成瘾和创伤性脑损伤的新型神经治疗药物。
J Neuroinflammation. 2019 Jan 23;16(1):14. doi: 10.1186/s12974-018-1393-0.
4
Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.增强型 DRα1 分子构建体与 CD74 结合和治疗 EAE 的效果增加。
Metab Brain Dis. 2019 Feb;34(1):153-164. doi: 10.1007/s11011-018-0331-2. Epub 2018 Oct 23.
5
MIF and D-DT are potential disease severity modifiers in male MS subjects.MIF 和 D-DT 可能是男性 MS 患者疾病严重程度的修饰因子。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.
6
Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease.治疗哮喘和慢性阻塞性肺疾病的双功能药物。
Eur Respir J. 2014 Aug;44(2):475-82. doi: 10.1183/09031936.00003814. Epub 2014 Apr 2.
7
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.用于治疗多发性硬化症的重组T细胞受体配体（RTL）：一项双盲、安慰剂对照的1期剂量递增研究。
Autoimmune Dis. 2012;2012:954739. doi: 10.1155/2012/954739. Epub 2012 Apr 5.
8
Characterization of human platelet binding of recombinant T cell receptor ligand.鉴定人源血小板对重组 T 细胞受体配体的结合
J Neuroinflammation. 2010 Nov 8;7:75. doi: 10.1186/1742-2094-7-75.
9
A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.一种治疗多发性硬化症的有前景的治疗方法：重组T细胞受体配体通过减少白细胞介素-17的产生和抑制致脑炎细胞向中枢神经系统的迁移来调节实验性自身免疫性脑脊髓炎。
J Neurosci. 2007 Nov 14;27(46):12531-9. doi: 10.1523/JNEUROSCI.3599-07.2007.
10
Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.重组 HLA-DP2 结合铍并使铍特异性致病性 CD4+ T 细胞产生耐受。
J Immunol. 2006 Sep 15;177(6):3874-83. doi: 10.4049/jimmunol.177.6.3874.